Jiamin Cao

Jiamin Cao

Auto-generated profile, based on publicly available information

Jiamin Cao

Department of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha City, Hunan Province, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Digital Health
Verified
Journal Article
Open access
JCJiamin Cao
Jiamin Cao
FZFeng Zhang
Feng Zhang
ZZZiyi Zhu
Ziyi Zhu
WXWei Xiong
Wei Xiong
Objective: Short videos are increasingly being used to disseminate health information. However, the quality of videos on common ophthalmic conditions such as cataract has not been systematically evaluated. Methods: This study employed a cross-sectional design. The TikTok platform was searched using the term “cataract” from 20:00 to 24:00 on 8 November 2024, without any restrictions. The top 100 retrieved videos were included in the study. They were rated using The Journal of American Medical Association ( JAMA ) benchmark criteria, Global Quality Score (GQS) scale, modified Decision-making Information Support Criteria for Evaluating the Reliability of Non-randomised Studies score, and Patient Education Materials Assessment Tool for Audio Visual Content. Videos by different groups were compared for quality and their underlying factors. Results: The top 100 videos had an average of 2009.1 likes, 795.65 comments, 2628.91 shares, and 554.08 saves. Their JAMA benchmark criteria, GQS, the modified Decision-making Information Support Criteria for Evaluating the Reliability of Non-randomised Studies score, and the Patient Education Materials Assessment Tool for Audio Visual Content score ratings differed ( p < .05) with account ownership, doctor rank, and video content. More videos were uploaded by institutions and physicians than by nonphysicians ( p < .05). The number of likes, comments, favorites, and shares of videos was not correlated with quality (Spearman correlation; p > .05). Further regression analysis confirmed that video quality can be predicted using account ownership. Conclusion: The quality of cataract-related short videos on platforms has room for improvement. Users may estimate video quality based on the identity of the content creator.

18 March 2023 in Redox Report
Verified
Journal Article
Open access
XFxianying fang
xianying fang
JCJiamin Cao
Jiamin Cao
ZTZhi Tao
Zhi Tao
ZYZhiqing Yang
Zhiqing Yang
YDYuan Dai
Yuan Dai
LZLinguo Zhao
Linguo Zhao
Objective: Hydroxytyrosol (HT) is a polyphenol with a wide range of biological activities. Excessive drinking can lead to oxidative stress and inflammation in the liver, which usually develop into alcohol liver disease (ALD). At present, there is no specific drug to treat ALD. In this paper, the protection effect of HT on ALD and the underline mechanism were studied. Methods: HepG2 cells were exposed to ethanol in vitro and C57BL/6J mice were fed with a Lieber-DeCarli ethanol liquid diet in vivo. Results: triglyceride (TG) level in serum and the expression of fatty acid synthase (FASN) were reduced significantly by the treatment with HT The acetaldehyde dehydrogenase (ALDH) activity was increased, the serum level of malondialdehyde (MDA) was decreased, catalase (CAT) and glutathione (GSH) were increased, suggesting that HT may reduce its oxidative damage to the body by promoting alcohol metabolism. Furthermore, according to the mRNA levels of tnf-α, il-6 and il-1β, HT inhibited ethanol-induced inflammation significantly. The anti-inflammatory mechanism of HT may be related to suppress the STAT3/iNOS pathway. Dissussion: Our study showed that HT could ameliorate ethanol-induced hepatic steatosis, oxidative stress and inflammation and provide a new candidate for the prevention and treatment of ALD. GRAPHICAL ABSTRACT

1 August 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JCJiamin Cao
Jiamin Cao
FZFeng Zhang
Feng Zhang
WXWei Xiong
Wei Xiong
Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

1 September 2024 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
HCHaiyan Chen
Haiyan Chen
JCJiamin Cao
Jiamin Cao
FZFeng Zhang
Feng Zhang
WXWei Xiong
Wei Xiong
Growing research proves gut microbiota and thyroid autoimmunity are linked. Graves’ disease (GD), as an autoimmune thyroid disease (AITD), is attributed to the production of thyroid-stimulating hormone receptor (TSHR) autoantibodies that bind to the thyroid follicular endothelial cells. It is well known that genetic factors, environmental factors, and immune disorders count for much in the development of GD. So far, the pathogenesis of GD is not elucidated. Emerging research reveals that the change in gut microbiota composition and its metabolites are related to GD. The gut microbial diversity is reduced in GDs compared with healthy controls (HCs). Firmicutes and Bacteroidetes account for a large proportion at the genus level. It is found that phyla Bacteroidetes increased while phyla Firmicutes decreased in Graves’ Disease patients (GD patients). Moreover, gut microbiota modulates the immune system to produce cytokines through bacterial metabolites. This article aims to find out the relation between gut microbiota dysbiosis and the development of GD. As more molecular pathways of bacterial metabolites are revealed, targeting microbiota is expected to the treatment of GD.

1 April 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
JCJiamin Cao
Jiamin Cao
FZFeng Zhang
Feng Zhang
HCHaiyan Chen
Haiyan Chen
BWBingxuan Wu
Bingxuan Wu
JYJiayang Yin
Jiayang Yin
WXWei Xiong
Wei Xiong
Background: Manifestations of thyroid-associated ophthalmopathy (TAO) vary greatly. Few tools and indicators are available to assess TAO, restricting personalized diagnosis and treatment. Aim: To identify an aptamer targeting thyroid-stimulating hormone receptor (TSHR) and utilize this aptamer to evaluate clinical activity in patients with TAO. Methods: An aptamer targeting TSHR was developed by exponential enrichment and systematic evaluation of TSHR ligands. After truncation and optimization, the affinity, equilibrium dissociation constant, and serum stability of this aptamer were evaluated. The affinity of the TSHR-targeting aptamer to isolated fibrocytes was assessed, as was aptamer internalization by fibrocytes. The mechanism of binding was determined by molecular docking. The correlation between disease manifestations and the percentage of TSHR-positive cells was assessed by correlation analysis. Results: The aptamer TSHR-21-42 was developed to bind to TSHR, with the equilibrium dissociation constant being 71.46 Kd. Isolated fibrocytes were shown to bind TSHR-21-42 through TSHR, with its affinity maintained at various temperatures and ion concentrations. TSHR-21-42 could compete with anti-TSHR antibody, both for binding site to TSHR and uptake by cells after binding. In addition, TSHR-21-42 could bind to leukocytes in peripheral blood, with this binding differing in patients with TAO and healthy control subjects. The percentage of TSHR-positive monocytes, as determined by binding of TSHR-21-42, correlated positively with clinical activity score in patients with TAO, indicating that TSHR-21-42 binding could assess the severity of TAO. Conclusion: This aptamer targeting TSHR may be used to objectively assess disease activity in patients with TAO, by evaluating the percentages of TSHR positive cells in peripheral blood.

28 September 2021 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
JCJiamin Cao
Jiamin Cao
NWNuo Wang
Nuo Wang
SHShiying Hou
Shiying Hou
XQXin Qi
Xin Qi
YCYu Chen
Yu Chen
WXWei Xiong
Wei Xiong
Background: Research on Graves ophthalmopathy has increased remarkably over the last 2 decades; however, few statistical analyses of the data presented in these publications have been conducted. Objective: This study aims to detect and analyze emerging trends and collaboration networks in Graves ophthalmopathy research. Methods: Graves ophthalmopathy–related publications from 1999 to 2019 were collected from the Web of Science Core Collection Database. Collected publications were restricted by category (article or review) and language (English). Bibliometric analyses included changes in the annual numbers of publications, journals, authors, countries, institutions, keywords, and references. Results: In total, 3051 publications that met the criteria were collected. The number of annual publications has exhibited an increasing trend over the last 20 years. The journal Thyroid ranked first, publishing 183 Graves ophthalmopathy–related studies. There was no evidence of a relationship between impact factor (IF) and the number of publications (P=.69). The author Smith TJ had the largest number of publications on Graves ophthalmopathy (n=83). Of the countries that had published Graves ophthalmopathy–related articles, the United States had the largest number (n=784) and the highest centrality (0.18). Among institutions, the University of Pisa (Italy) contributed the most Graves ophthalmopathy–related articles (n=114). The most recent burst keywords (proliferation, rituximab, and selenium) and references may provide clues on emerging trends in research and clinical practice. Conclusions: This bibliometric analysis highlights countries, institutions, and authors who contributed to Graves ophthalmopathy–related publications. Emerging trends in Graves ophthalmopathy research, based on burst keywords and references, may provide clues relevant to clinical practice and future research.